

International Speakers



Professor Alan Burnett

Cardiff University School of Medicine, UK

Alan K. Burnett was appointed chair and head of the Department of Haematology at the University of Wales College of Medicine (now Cardiff University) in 1992. In 2002, the National Cancer Research Institute was established in the UK and Professor Burnett was appointed as chair of the National Cancer Research Institute Haematological Oncology Study Group. He was appointed chair of the Medical Research Council Adult Leukaemia Working Party in 1989 and has acted as a coordinator of the MRC -10, -11, -12, -14, -15, -16, and -17 trials. Professor Burnett's main research interest is the development of treatments for acute myeloid leukemia. He has served on numerous advisory committees and is past president of the British Society of Haematology and chair of the UK National Training Program. He was elected as a Fellow of the Academy of Medical Science in 2002 and was awarded the Gold Medal of the British Society for Haematology in 2004, and was appointed as an MBE in the Queen's Birthday Honours for services to medicine in 2008.

Sponsored by Hospira



Professor Marco Cattaneo

Hematology and Thrombosis Unit, University of Milan, Italy

Marco Cattaneo is currently the Professor of Internal Medicine and the Director of the Hematology and Thrombosis Unit at the University of Milan, Italy. Since graduating from the same University in 1975, he developed a strong research record in haemostasis and thrombosis, with over 180 published peer-reviewed articles, and is the member of the editorial board of a number of prominent international journals. Current areas of research interest include the pathophysiology of primary hemostasis including the role platelet P2 receptors, the use of point of care devices to evaluate both anti-platelet therapy and bleeding disorders, and aspirin resistance.



Professor Martin Dreyling

University Hospital Großhadern, Ludwig Maximilians-University, Munich, Germany

Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University, Munich. He was visiting scientist at the University of Chicago 1992-1995. Dr Dreyling's scientific focus is on the molecular basis of malignant transformation and factors of susceptibility in lymphomagenesis, cell cycle dysregulation in mantle cell lymphoma (MCL) and secondary genetic alterations and biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches to indolent lymphoma, including radioactively labelled antibodies and non-myeloablative allogeneic transplantation. Dr Dreyling is Coordinator of the European MCL Network and Assistant Coordinator of the German Low Grade Lymphoma Study Group.



Professor Thierry Facon, France

Thierry Facon is Professor of Hematology in the Department of Hematology, Lille University Hospital, France, a position he has held since 2000. Professor Facon attained his MD at Lille University School of Medicine in 1987 and he became Assistant Professor of Hematology at Lille University Hospital in 1989. Between 2003 and 2006, Professor Facon was President of the French-speaking Myeloma Group (Intergroupe Francophone du Myélome [IFM]) and in 2005 he was appointed Vice President of the French Society of Hematology. Professor Facon has presented at several international congresses including ASCO 2006 plenary session. The author and co-author of a number of articles, his work has been published in various prestigious international journals such as the Lancet, New England Journal of Medicine and Blood.

Sponsored by Celgene



Professor Sergio Giralt

University of Texas MD Anderson Cancer Center, USA

Sergio Giralt joined the University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy as a Medical Oncology/Hematology Fellow in 1989. Among numerous administrative responsibilities, he is the Deputy Chair of the Department. Dr Giralt became involved with the International Bone Marrow Registry in 1992 and as a fellow proposed a study looking at the effects of interferon on transplant outcomes in Chronic Myelogenous Leukemia. Since that time, he has been heavily involved in many CIBMTR activities. He has chaired multiple sessions in the Tandem Meetings and has been an active participant in the nursing, data management and pharmacist symposiums. He is the Chair of the Center for International Blood and Marrow Transplant Research (CIBMTR). Dr Giralt's interests include minitransplant for acute leukemia and transplant for myeloma.



Dr Nigel Key

University of North Carolina at Chapel Hill, USA

Nigel Key is the Harold R Roberts Professor of Medicine at the University of North Carolina at Chapel Hill, USA. He is also Chief of the Hematology Section and Director of the Harold R Roberts Comprehensive Hemophilia Diagnostic and Treatment Center at UNC. Dr Key is a graduate of the Universities of St Andrew's and Manchester in the UK. He is currently President of the Hemophilia and Thrombosis Research Society of North America, a member of the Executive Committee of the World Federation of Hemophilia, and a Council member of the International Society of Thrombosis and Hemostasis.



Associate Professor Paul Kyrle

University Hospital, Vienna, Austria

Paul Kyrle is Associate Professor of Medicine at the University Hospital in Vienna, Austria. He also serves as the Head of the Karl Landsteiner-Institute of Clinical Thrombosis Research in Vienna, Austria. His scientific work is currently focused on elucidating the mechanisms leading to (recurrent) venous thrombosis and pulmonary embolism. He is the principal investigator of AUREC, one of the largest studies to investigate predictors and risk factors of recurrent venous disease. Paul Kyrle is the author of more than 150 articles in peer-reviewed journals and served as Congress President on the occasion of the 54th Annual Meeting of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH). He is also member of the German Academy of Sciences Leopoldina.




Professor Lena Napolitano

University of Michigan Health Systems, USA

Lena Napolitano is Professor of Surgery at the University of Michigan School of Medicine, Chief of Surgical Critical Care and Associate Chair for Critical Care for the Department of Surgery. She is a Fellow of the American College of Surgeons, American College of Critical Care Medicine, and the American College of Chest Physicians. Dr Napolitano is a member and holds leadership positions in numerous professional organizations in surgery, trauma and surgical critical care. Dr Napolitano has a research effort in trauma and surgical critical care, and is Principal Investigator on a number of research grants focused on translational research. She is a member of the Editorial Boards of the journals Surgical Infections, Journal of Surgical Research and New Surgery, Molecular Basis of Surgical Disease and New Technology. Dr Napolitano has received such honors as the 2002 Association of Women Surgeons Distinguished Member Award, awarded to a member that exemplifies the ideals and mission of the association.

International Speakers



Dr Paul Ness

Johns Hopkins University School of Medicine, Baltimore, USA

Paul Ness is director of the Transfusion Medicine Division at The Johns Hopkins Hospital and professor of Pathology, Medicine, and Oncology at The Johns Hopkins University School of Medicine in Baltimore, Maryland. From 1972-1974, Dr Ness was a staff associate in the Division of Blood Diseases and Resources of the National Heart, Lung, and Blood Institute at the National Institutes of Health in Bethesda, Maryland. Dr Ness has been a member of the AABB Board of Directors for many years and became President in 1999. He is a co-editor of two comprehensive texts in transfusion medicine, *The Scientific Basis of Transfusion Medicine and Blood Banking* and *Transfusion Medicine, Basic Principles and Practice*. Dr Ness has extensive experience in transfusion related research with emphasis upon transfusion related complications. He serves as PI for the Johns Hopkins site of the Transfusion Medicine Hemostasis Clinical Trial Network, funded by NHLBI. Dr Ness is the co-PI for a project funded by the REDS II program to study donor virus epidemiology issues in China.



Professor Martin L Olsson

Lund University, Lund, Sweden

Martin Olsson is a Professor of Transfusion Medicine at Lund University, Lund, Sweden and a Visiting Associate Professor/Lecturer at Harvard Medical School, Boston, MA, USA. His main clinical and research interests are in the molecular genetics of red cell surface markers with a special emphasis on carbohydrate histo-blood group systems and blood typing. His scientific contributions have focused on clarifying the correlation between red cell phenotypes and the underlying genetic polymorphisms, as well as glycosyltransferase function in different blood groups. He is also interested in pathogen-related aspects of blood group antigens and different mechanisms of protection against hemolysis, including exoglycosidase-treated red cells for ABO-universal transfusion. Dr. Olsson serves as Associate Editor of *Transfusion Medicine* and is a member of the Editorial Board of *Transfusion*. His awards include the Jean Julliard Prize from the International Society of Blood Transfusion, the Race and Sanger Award from the British Blood Transfusion Society, the Fernström Prize at Lund University and the Hain Foundation Prize.



Ms Sherri Ozawa

The Institute for Patient Blood Management, Englewood Hospital and Medical Center, USA

Sherri Ozawa has been involved in the field of patient blood management for more fifteen years. She serves as the Director of The Institute for Patient Blood Management at Englewood Hospital and Medical Center. Her background in critical care nursing enabled her to help create one of the largest multidisciplinary bloodless medicine and surgery programs in the world. She has lectured throughout the United States and internationally, with a particular focus on the nursing aspects of blood management. She has published numerous articles on the subject, and continues to be actively involved in research in the field of blood conservation, transfusion outcomes, and the economics of transfusion.



Professor Radek Skoda

University of Basel, Switzerland

Radek Skoda is the Professor of Molecular Medicine and chairs the Department of Research at the University Hospital Basel as well as the Department of Biomedicine, University of Basel, Switzerland. He has previously worked in Harvard Medical School and the German Cancer Research Centre. Professor Skoda was honoured with the 2007 American Society of Hematology Ham-Wasserman Lecture Award, speaking on his pioneering contributions to the molecular pathogenesis of myeloproliferative disorders, particularly the characterisation of c-mpl and the mutated form of JAK2.



Associate Professor Benny Sørensen

King's College London School of Medicine, London, UK

Benny Sørensen is a Senior Clinical Research Fellow and Honorary Lecturer at the Centre for Haemophilia and Thrombosis at Guy's and St Thomas NHS Foundation Trust and King's College London School of Medicine, London, UK; working as a co-ordinator and facilitator of a new Haemostasis Research Unit. His primary research areas are patients with congenital and acquired bleeding disorders and the recording of rate specific characteristics of whole blood clot formation in order to individually tailor haemostatic intervention. His special interests include patients suffering from severe haemophilia A and inhibitors as well as management of peri-operative bleeding. Dr Sørensen is a board member and scientific secretary of the Danish Society of Thrombosis and Haemostasis and part of the editorial advisory board of Journal of Thrombosis and Haemostasis.

Sponsored by CSL Bioplasma



Dr Daniel G Tenen

Harvard Medical School, USA

Daniel G Tenen is Professor of Medicine at Harvard Medical School, as well as Director of the Blood Program of the Harvard Stem Cell Institute, Director of the Cancer Biology Program at Beth Israel Deaconess Medical School, co-Director of the Harvard Medical School Hematology Training Grant, and Distinguished Visiting Professor at the National University of Singapore. His research efforts have focused on transcription factors, gene regulation, and their role in normal differentiation and cancer. His research contributions have included establishing the role of transcription factors in differentiation of myeloid cells and the role of disruption of these pathways in leukemia and lung cancer. He completed his research training as a postdoctoral fellow in David Liginstone's laboratory at Dana Farber Cancer Institute. He established his own independent laboratory at Beth Israel Deaconess Medical School, Harvard Medical School, in 1984.



Dr Dafydd Thomas

Morrison Hospital, Swansea, UK

Dafydd Thomas works as an Anaesthetist in Intensive Care Medicine in Swansea. He has been involved in postgraduate education since his appointment in 1989 and recently completed a period as an examiner for the RCA starting as a primary examiner in 1999 and finishing as a final examiner during the last academic year. During this time he has organised the South Wales Anaesthetic Course and the Morrison Critical Care Refresher. A busy and well traveled lecturer he has lately been seconded on a part time basis to the Welsh Blood Service to continue this work advocating and promoting appropriate use of blood components. He is currently President Elect of the BBTS (British Blood Transfusion Society), on the Board of Directors of NATA (International Network for the Advancement of Transfusion Alternatives), and chairs a working Party on cell salvage for the ISBT (International Society of Blood Transfusion).



Dr Neal S Young

National Heart, Lung and Blood Institute, NIH, USA

Neal S Young is Chief of the Hematology Branch of the National Heart, Lung and Blood Institute and Director of the new NIH Center for Human Immunology, Autoimmunity, and Inflammation. During a post-doctoral fellowship in molecular biology under Dr Arthur Nienhuis at the NHLBI, he developed an interest in aplastic anaemia and established an independent section to study human bone marrow failure. The clinic of the Branch is perhaps the major referral center for bone marrow failure syndromes in the world. Accomplishments from Dr Young's laboratory have included the successful development of immunosuppressive therapies for patients with aplastic anemia and related syndromes; the description of B19 parvovirus as an agent of human disease, including development of a vaccine now in clinical trials; the elucidation of both the immunology and genetics of acquired aplastic anemia, including the recent first demonstration of pathogenic mutations in TERT, the gene for the telomerase enzyme. Dr Young is co-discoverer on seven patents relating to parvoviruses and also the detection of mutations in human single hematopoietic cells.